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Abstract Using a cell-free assay designed to reconstitute cis-to-
medial intra-Golgi vesicular transport, we identified at least four
crude activities in bovine brain cytosol that stimulate this assay.
We have purified one of these activities to near homogeneity and
have identified this Mr 36 kDa protein to be the K isoform of
phosphatidylinositol transfer protein (PITPK) by N-terminal
peptide sequencing, immunoreactivity with PITP-specific anti-
sera, and the ability of recombinant PITPK to stimulate in vitro
intra-Golgi transport. From these data, we conclude that in vitro
Golgi transport is facilitated by PITPK.
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1. Introduction
All eukaryotic cells maintain discrete membrane-bounded
organelles which serve to compartmentalize cellular functions.
The anterograde and retrograde transport of proteins between
the organelles comprising the eukaryotic secretory pathway is
mediated by small membrane-bounded vesicles [1^3], and at
some steps, tubular or vesiculo-tubular carriers [4,5]. Trans-
port vesicles bud from one compartment, and then target to
and dock with the next compartment, where they fuse, thereby
releasing their cargo of proteins and lipids. The number and
variety of potential fusion partners for each transport inter-
mediate creates the need for a precise docking and fusion
mechanism to ensure the ¢delity and e⁄ciency of protein
tra⁄cking, and to maintain organelle integrity and identity.
An important ¢rst step in understanding the phenomenon of
protein transport and the mechanism of docking and fusion is
to identify the full set of factors that mediate these processes
and elucidate their individual roles in these events.
In an e¡ort to biochemically dissect protein transport and
to identify the factors involved, Rothman and colleagues de-
veloped an in vitro assay that reconstitutes protein tra⁄c
between the cis and medial cisternae of the Golgi apparatus
[6,7], which enabled the biochemical puri¢cation of N-ethyl-
maleimide-sensitive fusion protein (NSF) [8], K, L, and Q iso-
forms of soluble NSF attachment protein (SNAP) [9], p115
[10], and recently, p16 [11]. This cis-to-medial in vitro Golgi
transport assay has been suggested to reconstitute the entire
vesicular transport cycle of budding, docking, and fusion
[2,12], which is supported by the ¢nding that functional vesic-
ular intermediates can be isolated [13]. However, some data
raise the possibility that the assay may reconstitute a partial
reaction of transport comprised of only docking and fusion
[14^16]. Nevertheless, because the cis-to-medial Golgi trans-
port assay is dependent on NSF, the SNAPs, and p115, three
bona ¢de transport factors, the transport events measured in
the assay must be a speci¢c and regulated process re£ecting, at
the very least, the later stages of the vesicular transport cycle.
To purify additional protein tra⁄cking components, we
modi¢ed the in vitro cis-to-medial Golgi transport assay to
include functionally saturating levels of p115, NSF, and
SNAPs. The modi¢ed in vitro Golgi transport assay has
only a low level of activity in the absence of cytosol, indicat-
ing that at least one additional factor is required for full
activity, as had been previously suggested [10]. Indeed, using
this in vitro transport assay to test cytosolic fractions for
activity, we identi¢ed multiple crude activities in bovine brain
cytosol. We have biochemically puri¢ed one of these proteins
to near homogeneity. By multiple criteria, including size, N-
terminal peptide sequence analysis, immunoreactivity, and
studies with a recombinant protein, we have identi¢ed this
protein as the K isoform of phosphatidylinositol transfer pro-
tein (PITPK).
2. Materials and methods
2.1. Materials
Lec1 cell line (CRL 1735, ATCC, Rockville, MD [17]), anti-rat
PITPK polyclonal antibodies ([18]; a generous gift of J. Alb and V.
Bankiatis), polyclonal secondary antibodies (Jackson ImmunoRe-
search Laboratories, West Grove, PA), 125I-labeled goat anti-rabbit
IgG antibody (NEN, Boston, MA), His6-tagged K-SNAP, His6-tagged
Q-SNAP, and His6-tagged NSF constructs ([19]; generously provided
by S. Whiteheart), His6-tagged human PITPK construct ([20]; a kind
donation by P. Swigart and S. Cockcroft), 3H-UDP-N-acetylglucos-
amine (American Radiolabelled Chemicals, St. Louis, MO), L-K-phos-
phatidylcholine (Avanti Polar Lipids, Alabaster, AL). All other re-
agents were purchased from ACROS (Fisher Scienti¢c, Pittsburgh,
PA), Boehringer Mannheim (Indianapolis, IN), or Sigma Chemical
Company (St. Louis, MO).
2.2. General methods
Protein concentrations were assayed using the Bradford method
(Bio-Rad Laboratories, Hercules, CA) using BSA as a standard. All
chromatography, centrifugation, and concentration steps were per-
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formed at 4‡C. All material was clari¢ed by centrifugation at
10 000Ug for 10 min prior to chromatography. All samples were
dialyzed into transport assay bu¡er (25 mM HEPES-KOH, pH 7.4,
100 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT) prior
to analysis in the in vitro Golgi transport assay.
2.3. In vitro Golgi transport assay
The transport assay was performed as previously described [10],
with the following modi¢cations: the ‘donor’ Golgi membranes
were prepared from VSV-infected Lec1 cells [21] ; the ‘donor’ and
‘acceptor’ Golgi membranes were not salt-extracted, so they should
retain peripherally bound membrane proteins; reactions were incu-
bated at 35‡C for 90 min; and functionally saturating levels of
His6-NSF (325 ng), His6-K-SNAP (200 ng), His6-Q-SNAP (200 ng),
and p115 puri¢ed from bovine brain cytosol (100 ng) [10,19] were
included in each assay, along with 0.075 WCi 3H-UDP-GlcNAc (60
Ci/mmol), 3 Wl (about 1.5 Wg) ‘donor’ membranes, and 1 Wl (about 0.5
Wg) ‘acceptor’ membranes. For each assay, background was deter-
mined by omitting cytosol, and the complete, maximal signal was
determined with 2 Wl (128 Wg) of a 50% ammonium sulfate precipitate
of bovine brain cytosol (BBC50).
2.4. Electrophoresis, immunoblotting, and peptide sequencing
Proteins were separated by SDS-12% PAGE [22] and visualized by
Coomassie staining. Immunoblotting was performed according to
standard procedures [23]. Blots were developed using chemilumines-
cence (Amersham Life Science, Arlington Heights, IL). Antibody di-
lutions were as follows: rabbit anti-rat PITPK (recognizes both K and
L isoforms), 1:20 000; chicken anti-rat PITPK (K-isoform-speci¢c),
1:3000; HRP-conjugated goat anti-rabbit IgG, 1:2000; HRP-conju-
gated rabbit anti-chicken IgG, 1:5000; 125I-labeled goat anti-rabbit
IgG, 1:500. For the quantitative anti-PITP immunoblot used in Table
1, an 125I-labeled goat anti-rabbit IgG secondary antibody was used
for quantitation by PhosphorImaging (Molecular Dynamics, Image-
Quant software) using the puri¢ed bovine PITPK as a standard. For
our calculations, we assumed the bovine PITPK was 100% pure, which
is a slight overestimate. For peptide sequencing, the 36 kDa protein
was electrophoretically transferred to PVDF membrane (DuPont/
NEN), and the readily visible, unstained band was excised from the
blot and submitted to the Princeton University Synthesizing/Sequenc-
ing Facility for N-terminal peptide sequence determination using Ed-
man degradation chemistry.
2.5. Preparation of bovine p115 and recombinant proteins
p115 was puri¢ed from bovine brain cytosol as previously described
[10]. His6-K- and His6-Q-SNAPs as well as His6-NSF were puri¢ed as
described [19]. His6-PITPK was puri¢ed, and bacterial phospholipids
were exchanged for L-K-phosphatidylcholine as described [20]. His6-
PITPK was separated from unbound phospholipid by Superose 12 size
exclusion chromatography (Pharmacia Biotech, Piscataway, NJ).
2.6. Puri¢cation of Q1 p36K/bovine PITPK
2.6.1. Preparation of bovine brain cytosol. A 50% ammonium sul-
fate precipitate of bovine brain cytosol was prepared as previously
described (BBC50 [24]), and 17 700 mg of this material, derived
from 10 cow brains, was used as the starting material for the puri¢-
cation.
2.6.2. DEAE anion exchange and Cibacron blue 3GA dye a⁄nity
chromatography. BBC50 (450 ml) was dialyzed into bu¡er A (25
mM Tris-HCl, pH 8.5, 10 mM KCl, 10% glycerol (v/v), 1 mM
EDTA, 5 mM MgCl2, 1 mM DTT), diluted with bu¡er A to a ¢nal
concentration of 10 mg/ml (1780 ml ¢nal volume), and loaded at 2 ml/
min onto a 900 ml DEAE Sepharose Fast Flow column connected in
series to a 200 ml Cibacron blue 3GA column equilibrated in the same
bu¡er. After a 2 l wash with bu¡er A, the two columns were discon-
nected from each other, and the material that bound to the Cibacron
blue column was eluted with 600 ml of bu¡er B (25 mM Tris-HCl, pH
8.5, 500 mM KCl, 10% glycerol (v/v), 1 mM EDTA, 5 mM MgCl2,
1 mM DTT) and termed Blue Bound pool. The 430 ml Blue Bound
pool had 2.87 mg protein/ml.
2.6.3. Phenyl Sepharose chromatography. Solid KCl (62 g) was
added to the Blue Bound pool to raise the ¢nal conductivity to that
of phenyl bu¡er B (25 mM Tris-HCl, pH 8.5, 2.5 M KCl, 10% glyc-
erol (v/v), 1 mM EDTA, 5 mM MgCl2, 1 mM DTT), and then loaded
at 2 ml/min onto a 60 ml phenyl Sepharose column equilibrated in
phenyl bu¡er B. After a 220 ml wash in the same bu¡er, the column
was eluted with 460 ml of phenyl bu¡er A (25 mM Tris-HCl, pH 8.5,
10% glycerol (v/v), 1 mM EDTA, 5 mM MgCl2, 1 mM DTT) yielding
the 365 ml Phenyl Bound pool, which had 1.12 mg protein/ml.
2.6.4. Mono Q anion exchange chromatography. The Phenyl
Bound pool was dialyzed against Mono Q bu¡er A (25 mM Tris-
HCl, pH 9.0, 10% (v/v) glycerol, 1 mM EDTA, 5 mM MgCl2,
1 mM DTT) for 4 h to reduce the salt concentration. This partially
dialyzed Phenyl Bound pool was then concentrated to 100 ml using a
stirred-cell ultra¢ltration unit (Amicon, Beverly, MA) and dialyzed
again against Mono Q bu¡er A for 12^15 h. To avoid over-loading
the column, the dialyzed Phenyl Bound pool was divided in half, and
each half was loaded at 1 ml/min onto an 8 ml Mono Q HR10/10
column (Pharmacia) equilibrated in Mono Q bu¡er A. For each col-
umn run, after a 25 ml wash with Mono Q bu¡er A, the bound
material was eluted with a biphasic linear KCl gradient (0^250 mM
KCl in 52 ml, 250^500 mM KCl in 20 ml) in the same bu¡er. Assay of
the fractions revealed two main peaks of activity. The ¢rst peak eluted
at 50^100 mM KCl, and the second peak eluted at 110^150 mM KCl.
The fractions from the ¢rst peak of activity from both column runs
were pooled to generate the 14.4 ml Mono Q1 pool, which had 2.27
mg protein/ml.
2.6.5. Superose 12 size exclusion chromatography. The Mono Q1
pool was concentrated to 3 ml in a centrifugal ultra¢ltration unit
(Ultrafree-4 Biomax-10, Millipore, Bedford, MA), loaded at 0.3 ml/
min onto a 100 ml prep grade Superose 12 size exclusion column
(Pharmacia) equilibrated in 25 mM Tris-HCl, pH 7.4, 10 mM KCl,
1 mM DTT, 10% (v/v) glycerol, and eluted with the same bu¡er. The
broad peak of activity eluted at approximately 64 ml, corresponding
to an Mr of approximately 30 kDa. The active fractions were pooled,
yielding the 11 ml S12 pool, which had 0.39 mg protein/ml.
2.6.6. Hydroxylapatite chromatography. The S12 pool was ad-
justed to a ¢nal concentration of 1 mM potassium phosphate (KPi)
by the addition of 1 M KPi, pH 7.4, and then loaded at 0.5 ml/min
onto a 2 ml Bio-scale ceramic hydroxylapatite column (Bio-Rad) equi-
librated in 25 mM Tris-HCl, pH 7.4, 10 mM KCl, 1 mM DTT, 10%
(v/v) glycerol, 1 mM KPi, pH 7.4. The bound material was eluted with
a biphasic linear KPi gradient (1^100 mM KPi in 12 ml, 100^500 mM
KPi in 4 ml) in the same bu¡er. Assay of gradient fractions revealed a
peak of activity that eluted between 45 and 65 mM KPi. These active
fractions were pooled to generate the 1.5 ml HAP pool, which had
0.57 mg protein/ml.
2.6.7. Superdex 75 size exclusion chromatography. Approximately
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Table 1
Summary of Q1 p36K/PITPK puri¢cation
Puri¢cation step mg protein Protein yield (%) mg PITPa PITP yielda (%) Speci¢c activity (cpm/Wg)
BBC50 17 700 100 36.3 100 103
Blue Bd 1 230 6.9 10.2 28 99
Phenyl Bd 409 2.3 11.4 31 427
Mono Q 32.7 0.18 4.3 12 231
Superose 12 4.3 0.024 2.1 5.8 370
Hydroxylapatite 0.85 0.0048 0.66 1.8 260
Superdex 75b 0.30 0.0017 0.30 0.8 320
aWe used quantitative immunoblotting and PhosphorImager analysis to determine the PITPK concentration and % yield of PITPK at each
puri¢cation step.
bIn the puri¢cation we only used half of the hydroxylapatite pool for subsequent puri¢cation on Superdex 75. Thus, the numbers in this row
represent the theoretical yield of the puri¢cation had we not halved the preparation prior to Superdex 75 size exclusion chromatography.
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half of the hydroxylapatite pool (0.78 ml) was applied at 0.2 ml/min to
a 24 ml Superdex 75 Pharmacia column equilibrated in 20 mM
HEPES-KOH, pH 7.4, 200 mM KOAc, 5 mM Mg(OAc)2, 1 mM
DTT, 1 mM EDTA and eluted with the same bu¡er. The active
fractions were pooled, yielding 1 ml of a highly puri¢ed preparation
of Q1 p36K/PITPK, which was 0.15 mg/ml.
3. Results
In the absence of crude cytosol, the modi¢ed cis-to-medial
Golgi transport assay (using non-salt-extracted membranes
and assayed in the presence of NSF, K- and Q-SNAPs, and
p115) yielded a low level of activity (Fig. 1A). However, when
a 50% ammonium sulfate precipitate of bovine brain cytosol
(BBC50) was titrated into the assay, the activity increased
nearly seven-fold. This result indicated that the modi¢ed Gol-
gi transport assay requires supplementation with at least one
cytosolic factor necessary for full activation. To purify the
factor(s) required for full stimulation, we biochemically frac-
tionated BBC50 and assayed the fractions for their ability to
stimulate the modi¢ed intra-Golgi transport assay.
As a ¢rst step, BBC50 was fractionated by DEAE anion
exchange chromatography, and the DEAE load (Ld), £ow-
through (FT), and bound (Bd) pools were assayed for trans-
port activity. Both the FT and Bd material possessed in vitro
Golgi transport activity (Fig. 1B). The speci¢c activities of the
Ld (103 cpm/Wg) and FT (97 cpm/Wg) were similar, whereas
that of the Bd (66 cpm/Wg) was lower. The di¡ering plateau
levels of the FT and Bd, coupled with their di¡ering migra-
tions on a size exclusion column (data not shown), indicated
that DEAE anion exchange chromatography separated
BBC50 into two distinct activities. The puri¢cation of one
of the DEAE Bd activities, which was shown to be a novel
13S protein complex, will be described elsewhere (Walter et
al., submitted). The puri¢cation of the DEAE FT activity is
presented below.
The DEAE FT was subjected to dye a⁄nity and phenyl
hydrophobic interaction chromatography steps, where it be-
haved as a single activity. However, the next step, Mono Q
anion exchange chromatography, revealed the presence of
multiple activities. The FT material of the Mono Q showed
some activity, and elution of the material bound to the Mono
Q column with a linear salt gradient revealed two peaks of
activity: Q1 and Q2 (Fig. 1C). These two peaks, though re-
producible, were never completely resolved from each other.
A third peak was sometimes seen (asterisk in Fig. 1C), and
based on its size exclusion pro¢le, we attributed this peak to
DEAE Bd material that had contaminated the DEAE FT
(data not shown).
The Q1 activity was further puri¢ed by a combination of
Superose 12 size exclusion, hydroxylapatite, and Superdex 75
size exclusion chromatography steps, resulting in an essen-
tially pure preparation of a 36 kDa protein that comigrated
with a single peak of activity (Fig. 2A,B). Interestingly, this
protein had an apparent molecular weight by SDS-12%
PAGE of 36 kDa, but an Mr of about 15 kDa by size ex-
clusion chromatography (see below). When titrated into the
Golgi transport assay, the puri¢ed 36 kDa protein (Q1 p36K)
yielded a maximal two-fold stimulation (compared to seven-
fold for BBC50) and a speci¢c activity of 320 cpm/Wg (Fig.
2C), only a three-fold enhancement over BBC50 (see Table 1
and Section 4). Further titration of Q1 p36K decreased trans-
port activity (data not shown). A Coomassie-stained gel of
fractions from the puri¢cation is shown in Fig. 2D. Table 1
summarizes the puri¢cation shown in Figs. 1 and 2.
Determination of the N-terminal peptide sequence of the
Q1 p36K protein and subsequent database searches yielded
a nearly perfect match with the K isoform of the rat, mouse,
human, and rabbit phosphatidylinositol transfer proteins,
PITP (Fig. 3A), the only di¡erence being a conserved gluta-
mate-to-aspartate change, which probably represents a species
di¡erence [25]. PITP is a phospholipid binding protein with a
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Fig. 1. Identi¢cation of three crude Golgi transport activities in bo-
vine brain cytosol. A: BBC50 was titrated into the in vitro Golgi
transport assay in the presence of p115, NSF, K-SNAP, and Q-
SNAP. B: BBC50 was chromatographed on a DEAE anion ex-
change column, and the DEAE load (Ld; ¢lled circles), £ow-
through (FT; open squares), and bound (Bd; open triangles) were
titrated into the Golgi transport assay. The background (830 cpm)
was subtracted, yielding the data shown. The assay maximum was
4243 cpm. C: After DEAE, Cibacron blue dye a⁄nity, and phenyl
chromatography steps, the Phenyl Bd pool was loaded onto a
Mono Q column and eluted with KCl. The Mono Q Ld and FT
pools (bars) and column fractions (diamonds) were assayed for Gol-
gi transport activity. Three peaks of activity are evident: Q1, Q2,
and a third peak (asterisk) that represents a contaminating activity.
The assay maximum was 3289, and the background (927 cpm) was
subtracted.
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high a⁄nity for phosphatidylinositol (PI), which can e¡ect the
net transfer of phospholipids between membranes in vitro
(reviewed in [26]). Within a given species, e.g. rat, the K and
L isoforms of PITP are approximately 77% identical [27,28],
whereas the interspeci¢c identity within isoforms is much
higher, 98^99% [29]. Thus, given the high conservation of
the mammalian PITP sequences, the PITPL N-terminal se-
quence is clearly distinct from the PITPK and the Q1 p36K
sequences.
Consistent with the peptide sequence data, immunoblotting
analysis of Q1 p36K using an K-isoform-speci¢c polyclonal
antibody generated against rat PITPK indicated that Q1
p36K and PITPK are immunologically related (Fig. 3B, left
panel). In addition, we analyzed the same samples using a
polyclonal antibody that recognizes both the K and L isoforms
of PITP. Analysis with this bi-speci¢c antibody showed that
the signal obtained from 20 ng of His6-tagged recombinant
PITPK (rP) was similar to the signal from 20 Wg of both rat
and bovine brain cytosols (R, B; Fig. 3B, right panel) indicat-
ing an approximate abundance of PITP in cytosol of 0.1%. A
similar estimation using the K-speci¢c antibodies yielded the
same result (Fig. 3B, left panel), suggesting that the K isoform
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Fig. 3. Q1 p36K is the K isoform of phosphatidylinositol transfer
protein (PITPK). A: The N-terminal peptide sequence of Q1 p36K
is shown (p36) along with the N-terminal sequence of the K (PK)
and L (PL) isoforms of PITP from human, mouse, rabbit, and rat.
The identity of the 13th residue of Q1 p36K was ambiguous (X)
upon sequencing. Identical residues to p36 are indicated in open
text, conserved residues are boxed, and unconserved residues are in
reverse text. B: Duplicates of 20 Wg each of rat brain cytosol (R)
and BBC50 (B), along with 20 ng each of p36K/bovine PITPK (P)
and recombinant human PITPK (rP), were resolved by SDS-12%
PAGE and blotted to PVDF membrane. One half of the blot was
probed with a polyclonal anti-PITPK antibody speci¢c for the K iso-
form (left panel), while the other half was probed with a polyclonal
anti-PITPK antibody that recognizes both the K and L isoforms
(right panel). The slower migration of the recombinant protein is
due to the His6-tag. C: Recombinant human PITPK (rPITP) was
prepared and titrated into the Golgi transport assay. The recombi-
nant PITPK stimulated the assay, with a speci¢c activity of 97 cpm/
Wg. The background (529 cpm) was subtracted. The assay maximum
was 4605 cpm.
Fig. 2. Puri¢cation of the Q1 activity reveals it to be a 36 kDa pro-
tein. A: The hydroxylapatite pool was chromatographed on Super-
dex 75 size exclusion, and the Ld (bar) and column fractions
(circles) were assayed for transport activity. A single peak of activity
(fractions 25 and 26) was evident, with an Mr of about 15 kDa.
The assay maximum was 3650, and the background (527 cpm) was
subtracted, yielding the data shown. B: A Coomassie-stained gel of
the Superdex 75 Ld and column fractions shown in A. The major
36 kDa band corresponds to the transport activity observed in A.
C: Fractions 25 and 26 were pooled and titrated into the Golgi
transport assay. The background (581 cpm) was subtracted. The as-
say maximum was 4124. D: A Coomassie-stained gel of column
pools from the puri¢cation. The lanes, from left to right, contain 10
Wg each of BBC50 (BC), DEAE FT (D), and Blue Bd (Bl); 6 Wg of
phenyl Bd (Ph); 3 Wg of Mono Q1 (Q); 2 Wg of Superose 12 (S12);
and 1 Wg each of hydroxylapatite (H) and Superdex 75 (S75) pools.
In the last lane, the higher molecular weight bands are contami-
nants not present in the Superdex 75 fractions (see B), and the al-
tered mobility of the 36 kDa protein was not reproducible.
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may constitute the majority of PITP present in rat and bovine
brain cytosols. This may be because PITPL is associated with
the Golgi in vivo [25] and therefore could have been discarded
along with the cellular membrane fraction during our prepa-
ration of the cytosols.
Final con¢rmation of the identi¢cation of Q1 p36K as
PITPK came from studies using a recombinant human His6-
tagged PITPK. When titrated into the in vitro intra-Golgi
transport assay, puri¢ed recombinant human His6-tagged
PITPK also stimulated the assay, with a speci¢c activity of
97 cpm/Wg (Fig. 3C). Although the variation in activity be-
tween preparations of the bovine PITPK and recombinant
PITPK complicated the determination of comparative speci¢c
activities, in general, the speci¢c activity of the recombinant
protein ranged from 26 to 97 cpm/Wg whereas the speci¢c
activity of the bovine PITPK ranged from 107 to 345 cpm/
Wg (data not shown). Curiously, the discovery that Q1 p36K is
PITPK served to explain its aberrantly slow migration on
Superdex 75 size exclusion (Fig. 2A,B), as this anomalous
behavior on size exclusion is typical of PITP [30].
To determine the concentration of PITPK at each step of
the puri¢cation and to evaluate the puri¢cation of PITPK in
comparison to bulk protein, we performed a quantitative im-
munoblotting analysis of the puri¢cation fractions using an
125I-labeled secondary antibody (Table 1). Because the epitope
recognized by the K-speci¢c antibody is easily lost or de-
graded, potentially complicating quantitation (data not
shown), we used the anti-rat PITP antibody that recognizes
both the K and L isoforms for our analysis. Due to the low
levels of PITPL compared to PITPK in BBC50 (see Fig. 3B),
cross-reactivity with the L isoform should be minimal. Using
this method, we determined that PITPK is a fairly abundant
protein in brain, representing about 0.2% of BBC50, which is
in good agreement with our chemiluminescence-based deter-
mination of about 0.1% (Fig. 3B). The puri¢cation resulted in
a 0.8% yield of PITPK compared to a 0.0017% yield of total
protein, indicating a 500-fold enrichment of PITPK over total
protein. The 0.0017% yield of PITP relative to total protein is
comparable to other published PITP puri¢cations [31,32].
4. Discussion
We have presented the puri¢cation of PITPK, a phospho-
lipid binding protein, from bovine brain cytosol using an in
vitro assay that reconstitutes cis-to-medial intra-Golgi trans-
port. Of the two isoforms of PITP, K and L, only K was
puri¢ed. However, because the K isoform is the predominant
one in our cytosol preparations (see Fig. 3B) these results do
not exclude the possibility that the L isoform is also capable of
stimulating intra-Golgi transport. Indeed, in in vitro assays
where both the K and L isoforms were tested, both isoforms
were shown to be active [33^35].
Although PITPK is clearly active in the intra-Golgi trans-
port assay, its speci¢c activity is rather low, which might be
accounted for by two factors. First, in addition to NSF, the
SNAPs, and p115, at least four activities constitute the activ-
ity of BBC50, and all of these may be required for full activ-
ity. Thus, as the PITPK activity is puri¢ed away from the
others, its speci¢c activity and maximal level of stimulation
may drop or stay level, rather than increase. For some steps
of the puri¢cation, this seemed to be the case (see Table 1).
Second, like others, we found PITPK to be a very labile pro-
tein [30]. Therefore, it is likely that we had partly inactivated
the protein in the course of its puri¢cation, further contrib-
uting to an underestimation of the ¢nal speci¢c activity. On
the other hand, the concentration of bovine PITP required in
the assay for maximal stimulation (80 Wg/ml) is similar to that
required for PC transfer [20] and the reconstitution of PLC
signaling [33], though much higher than that required for PI
transfer [34] or secretory vesicle formation [35].
Previous biochemical studies in mammalian cells have im-
plicated a role in secretion for PITP in both the processes of
vesicle formation from the TGN [35,36] and secretory vesicle
priming, a post-docking event required for subsequent fusion
at the plasma membrane [37]. Similarly, in yeast PITP mu-
tants, the observed protein transport block through the Golgi
apparatus may result from defects in both vesicle budding and
fusion [38]. Taken together, the above genetic and biochemical
data suggest that PITP plays a dual role in vesicular trans-
port, a¡ecting both the formation and consumption of
vesicles. Interestingly, experiments using permeabilized mam-
malian cells have indicated that PITP plays yet a third role in
mammalian cells as a necessary component of the phospholip-
ase C (PLC)-mediated inositol-lipid signal transduction path-
way [39^41].
Studies aimed at elucidating the mechanism of action of
PITP in each of these seemingly disparate processes have
yielded a singular theme: the activity of PITP stems from
its ability to remodel/modulate the phospholipid composition
of the membrane bilayer. Not only can PITP selectively ex-
change one phospholipid for another [34], but it can stimulate
the local synthesis of phosphatidylinositol-4,5-bisphosphate
(PIP2) by presenting phosphatidylinositol (PI) to the phospho-
kinases involved in polyphosphoinositide synthesis [33,42^44].
Furthermore, in yeast, PITP can a¡ect the diacyglycerol pool
in Golgi membranes through the dual regulation of the bio-
synthesis of phosphatidylcholine (PC) and inositol-sphingo-
lipids [45].
Regardless of whether the in vitro Golgi transport assay
operates via a vesicular intermediate [13] or simply through
membrane docking and fusion [14,16], PITPK may be acting
by remodeling the phospholipid content of the membranes. By
increasing the synthesis of PIP2 and other polyphosphoinosi-
tides or modulating the abundance of a speci¢c phospholipid
pool, such as PC or diacyglycerol, PITP could alter the bio-
physical properties of the membrane or generate binding sites
for the recruitment of proteins [46^48]. The identi¢cation of
PITPK as a factor capable of stimulating in vitro intra-Golgi
transport con¢rms the critical role that PITP plays in secret-
ory transport and highlights the importance of phospholipids
and the membrane environment for in vitro transport assays
as well as for the in vivo biological processes they were de-
signed to model. Future study of the role of PITP in Golgi
transport and other secretory events may serve to clarify the
role of phospholipids and membranes as active players in the
process of vesicular transport.
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